Systemic lupus erythematosus (SLE) is the most common form of lupus and affects some 70% of people who are diagnosed with lupus. SLE can affect multiple organs and systems, including the skin, kidneys, joints, brain and heart. While anyone can develop SLE, some groups, including women between the ages of 15 and 44, certain ethnic groups and those with a family history of autoimmune diseases, are at an increased risk for SLE.
Providence Swedish is a site for two investigational studies of new medications to treat SLE. If you have been diagnosed with SLE and meet certain criteria, you may be eligible to participate. To learn more, call our senior research coordinator at (206) 386-2240, or email Rheumatology.Research@swedish.org.
The Topaz study is enrolling people with flaring to moderate SLE.The drug is being studied as a potential treatment for a lupus-related skin disease known as cutaneous lupus erythematosus (CLE).
POETYK SLE-1 (IM011-246) and POETYK SLE-2 (IM011-247) are two identical SLE clinical trials evaluating the safety and effectiveness of an investigational study medication in adults with active SLE.
About Providence Swedish
Providence Swedish has served the Puget Sound region since the first Providence hospital opened in Seattle in 1877 and the first Swedish hospital opened in 1910. The two organizations affiliated in 2012 and today comprise the largest health care delivery system in Western Washington, with 22,000 caregivers, eight hospitals and 244 clinics throughout Western Washington – from Everett to Centralia. A not-for-profit family of organizations, Providence Swedish provides more than $545 million in community benefit in the Puget Sound region each year. The health system offers a comprehensive range of services and specialty and subspecialty care in a number of clinical areas, including cancer, cardiovascular health, neurosciences, orthopedics, digestive health and women’s and children’s care.
